Please use this identifier to cite or link to this item:
|Title:||Annexin A1 influences in breast cancer: Controversies on contributions to tumour, host and immunoediting processes.||Austin Authors:||Tu, Yan;Johnstone, Cameron N ;Stewart, Alastair G||Affiliation:||Department of Pharmacology and Therapeutics, The University of Melbourne, Parkville, Melbourne, Australia
Cancer & Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
|Issue Date:||May-2017||metadata.dc.date:||2017-02-14||Publication information:||Pharmacological research 2017; 119: 278-288||Abstract:||Annexin A1 is a multifunctional protein characterised by its actions in modulating the innate and adaptive immune response. Accumulating evidence of altered annexin A1 expression in many human tumours raises interest in its functional role in cancer biology. In breast cancer, altered annexin A1 expression levels suggest a potential influence on tumorigenic and metastatic processes. However, reports of conflicting results reveal a relationship that is much more complex than first conceptualised. In this review, we explore the diverse actions of annexin A1 on breast tumour cells and various host cell types, including stromal immune and structural cells, particularly in the context of cancer immunoediting.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/17662||DOI:||10.1016/j.phrs.2017.02.011||Journal:||Pharmacological research||PubMed URL:||28212890||Type:||Journal Article||Subjects:||Annexin A1
|Appears in Collections:||Journal articles|
Show full item record
checked on Jan 26, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.